Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns Page 1

Approval expands NexoBrid target group to approximately 20 pediatric burn centers

CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or partial-thickness burns.

“We are pleased that the FDA has approved NexoBrid for pediatric use as it offers a novel, non-surgical solution for treating severe burns in this vulnerable pediatric patient population,” said Nick Colangelo, President and CEO of Vericel. “We believe NexoBrid is poised to become the new standard of care for eschar removal and to have a meaningful impact on the lives of adult and pediatric burn patients, and we look forward to executing on our commercial launch of NexoBrid.”